Cingulate (CING) Projected to Post Quarterly Earnings on Monday

Cingulate (NASDAQ:CING) is expected to be announcing its earnings results before the market opens on Monday, April 7th. Analysts expect the company to announce earnings of ($1.48) per share for the quarter.

Cingulate Price Performance

CING stock opened at $3.78 on Friday. Cingulate has a 1 year low of $1.80 and a 1 year high of $20.83. The company has a market cap of $12.14 million, a P/E ratio of -0.26 and a beta of -0.83. The stock’s fifty day moving average price is $4.19 and its 200-day moving average price is $4.42.

Analysts Set New Price Targets

Several research analysts have issued reports on CING shares. Roth Capital raised Cingulate to a “strong-buy” rating in a research report on Friday, January 10th. Roth Mkm assumed coverage on shares of Cingulate in a report on Friday, January 10th. They issued a “buy” rating and a $12.00 price objective on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Cingulate in a report on Thursday, March 6th.

About Cingulate

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.